Ticker

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq…

Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or…

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly.